Scancell Holdings Plc (SCNLF)
OTC PINK OTC PINK Primary 
Scancell's latest deal is only part of the story for this ambitious cancer vaccine specialist
For ambitious junior life sciences companies, often the ultimate goal is securing partnerships with well-funded industry players to propel drug development toward commercial success. For many smaller innovators, bringing a promising molecule from the lab through clinical trials and onto the market is a daunting challenge requiring significant time and financial resources.
Scancell Holdings shares jump 9% following high-value licensing announcement
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) shares are up 9% this Wednesday after the clinical-stage biotech company announced a licensing agreement with Genmab (CSE:GEN) worth up to $630 million in payments. The agreement grants Genmab exclusive global rights to develop and commercialise a monoclonal antibody from Scancell's GlyMab platform.
Scancell strikes deal worth up to $630m with Genmab
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish biotech exclusive global rights to develop and commercialise a monoclonal antibody from the UK drug developer's GlyMab platform.
Scancell's new CEO takes the helm of a cancer immunotherapy specialist in rude health
Dr Phil L'Hullier begins his tenure as CEO of Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) at a pivotal moment, coinciding with significant clinical progress for its lead asset, SCIB1. This DNA-based cancer vaccine has shown promise in treating advanced melanoma, but Scancell's investment story goes beyond a single treatment.
Scancell trial update 'very positive', says broker
Panmure Liberum repeated its 'buy' recommendation for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) shares after what it described as a 'very positive' update from its phase II SCOPE clinical trial. The study is designed to assess the potential of the cancer vaccine, SCIB1.
Scancell's chief scientist hails 'excellent' melanoma data
Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) chief scientist, Professor Lindy Durrant, hailed results from the ongoing SCOPE trial for advanced melanoma as “excellent”. The study tested Scancell's SCIB1 immunotherapy in combination with two checkpoint inhibitor drugs, ipilimumab and nivolumab, in 25 patients.
Scancell appointment wins City favour as shares rise 11%
The appointment of Dr. Phil L'Huillier as CEO brings essential company development expertise to Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), enhancing its strong scientific foundation and helping the company progress to its next stage of growth.
Scancell names Dr Phil L'Huillier new CEO
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a company developing immunotherapies to treat cancer, has appointed Dr Phil L'Huillier as its new chief executive. He will officially join the company on November 18.
Scancell Holdings sets ambitious roadmap for the next 18 months
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has rolled out its roadmap for the next 18 months, which builds on the significant clinical progress made to date. An early milestone comes from the release of full cohort data for SCIB1 and iSCIB1+ (for melanoma) in late 2024 and early 2025.
Scancell ‘in a strong position for raising funding' says Panmure
Broker Panmure Liberum has reiterated its buy rating on Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s shares with a target price of 23.3p after Scancell announced a strategic partnership with PharmaJet for the supply of the Stratis intramuscular (IM) needle-free injection system. Scancell will use PharmaJet's Stratis needle-free intramuscular delivery system for its SCIB1/iSCIB1+ DNA cancer vaccine.
Scancell partners with ParmaJet for needle-free cancer vaccine delivery
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has signed a strategic partnership with PharmaJet for the supply of the Stratis intramuscular (IM) needle-free injection system. The system will be used for the delivery of Scancell's SCIB1/iSCIB1+ DNA cancer vaccine for patients with advanced or metastatic melanoma.
Scancell Holdings appoints experienced chief medical officer
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a developer of immunotherapies for cancer treatment, has appointed Dr Nermeen Varawalla as chief medical officer, effective immediately. Varawalla brings over 25 years of experience in global pharmaceutical companies, healthcare consultancy, and clinical trial services.
